New study monitors Repotrectinib's safety in korean cancer patients
NCT ID NCT07599007
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This observational study follows about 10 Korean patients with advanced ROS1-positive lung cancer or NTRK fusion solid tumors who are already receiving the drug repotrectinib as part of routine care. Researchers will track side effects and tumor response over up to 12 months to understand how the drug works in real-world settings. The goal is to gather safety and effectiveness data, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Bristol Myers Squibb Pharmaceutical Korea Ltd
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.